先天性心脏病儿童13价肺炎球菌多糖结合疫苗免疫效果及安全性的研究进展  

Research progress on immune efficacy and safety of 13-valent pneumococcal polysaccharide conjugate vaccine in children with congenital heart disease

作　　者：张瑞 程琬然 陈琳琰 王卫平 冯勇 邓鹏飞 ZHANG Rui;CHENG Wanran;CHEN Linyan;WANG Weiping;FENG Yong;DENG Pengfei(Department of Immunology and Prevention,Shanghai Pudong District Center for Diseases Control and Prevention,Fudan University Pudong Institute of Preventive Medicine,Shanghai,200136,China)

机构地区：[1]上海市浦东新区疾病预防控制中心免疫预防科,复旦大学浦东预防医学研究院,上海200136

出　　处：《职业与健康》2024年第11期1581-1584,共4页Occupation and Health

基　　金：上海市浦东新区卫生健康委员会重点学科(PWZxk2022-25);上海市浦东新区卫生健康委员会学科带头人培养计划(PWRd2020-14);上海市浦东新区疾病预防控制中心课题(PDCDC2021-05);上海市优秀青年人才项目(GWV-10.2-YQ38)。

摘　　要：先天性心脏病(congenital heart disease,CHD)儿童感染肺炎链球菌后发展为肺炎重症及死亡的风险较高,近年来,CHD儿童13价肺炎球菌多糖结合疫苗(13-valent pneumococcal polysaccharide conjugate vaccine,PCV13)免疫效果相关研究被诸多医疗专家所关注。本文通过检索中国知网、维普、万方、Pubmed等数据库,就PCV13在CHD儿童中免疫效果及安全性相关研究进展进行综述,为CHD儿童PCV13接种提供参考依据。Children with congenital heart disease(CHD)are at high risk of developing severe pneumonia and death after being infected with Streptococcus pneumoniae.In recent years,research on the immune effect of 13-valent pneumococcal polysaccharide conjugate vaccine(PCV13)in children with CHD has attracted the attention of many medical experts.This article reviews the research progress on the immune effect and safety of PCV13 in CHD children by searching databases such as China National Knowledge Infrastructure(CNKI),VIP,Wanfang,Pubmed,etc.,providing reference for PCV13 vaccination in CHD children.

关 键 词：13价肺炎球菌多糖结合疫苗 先天性心脏病 肺炎球菌性肺炎 免疫效果 安全性 

分 类 号：R186[医药卫生—流行病学]